Cargando…
VACCINATIONS | Viral
Vaccines are preparations of weakened or killed viruses or viral subunits that trigger specific protective immunity. Vaccination is the single most effective tool for preventing communicable disease, highlighted by the achievements of the smallpox and poliomyelitis eradication programs and the rise...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150349/ http://dx.doi.org/10.1016/B0-12-370879-6/00418-X |
_version_ | 1783521009897308160 |
---|---|
author | Olszewska, W. Openshaw, P.J.M. Helson, R. |
author_facet | Olszewska, W. Openshaw, P.J.M. Helson, R. |
author_sort | Olszewska, W. |
collection | PubMed |
description | Vaccines are preparations of weakened or killed viruses or viral subunits that trigger specific protective immunity. Vaccination is the single most effective tool for preventing communicable disease, highlighted by the achievements of the smallpox and poliomyelitis eradication programs and the rise in infections for which no effective vaccine is available: human immunodeficiency virus, malaria, worms, and tuberculosis. World Health Organization initiatives target acute respiratory diseases in infancy and early childhood with novel immunization approaches. Effective vaccines are needed urgently for viral respiratory diseases, but progress has been disappointingly slow. Vaccine candidates often show reduced efficacy in infancy, in partially immune adults, the immunocompromised, and the elderly. However, several promising vaccines are in clinical trial, and it is likely that vaccines against respiratory syncytial virus and parainfluenza will be licensed within the next 5–10 years. Mucosally delivered influenza vaccine is now available, and novel adjuvants offer the prospect of better immunogenicity. Ideally, multivalent mucosal vaccines will be developed that provide protection against a spectrum of respiratory infections in specific target age groups. |
format | Online Article Text |
id | pubmed-7150349 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
record_format | MEDLINE/PubMed |
spelling | pubmed-71503492020-04-13 VACCINATIONS | Viral Olszewska, W. Openshaw, P.J.M. Helson, R. Encyclopedia of Respiratory Medicine Article Vaccines are preparations of weakened or killed viruses or viral subunits that trigger specific protective immunity. Vaccination is the single most effective tool for preventing communicable disease, highlighted by the achievements of the smallpox and poliomyelitis eradication programs and the rise in infections for which no effective vaccine is available: human immunodeficiency virus, malaria, worms, and tuberculosis. World Health Organization initiatives target acute respiratory diseases in infancy and early childhood with novel immunization approaches. Effective vaccines are needed urgently for viral respiratory diseases, but progress has been disappointingly slow. Vaccine candidates often show reduced efficacy in infancy, in partially immune adults, the immunocompromised, and the elderly. However, several promising vaccines are in clinical trial, and it is likely that vaccines against respiratory syncytial virus and parainfluenza will be licensed within the next 5–10 years. Mucosally delivered influenza vaccine is now available, and novel adjuvants offer the prospect of better immunogenicity. Ideally, multivalent mucosal vaccines will be developed that provide protection against a spectrum of respiratory infections in specific target age groups. 2006 2006-05-13 /pmc/articles/PMC7150349/ http://dx.doi.org/10.1016/B0-12-370879-6/00418-X Text en Copyright © 2006 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Olszewska, W. Openshaw, P.J.M. Helson, R. VACCINATIONS | Viral |
title | VACCINATIONS | Viral |
title_full | VACCINATIONS | Viral |
title_fullStr | VACCINATIONS | Viral |
title_full_unstemmed | VACCINATIONS | Viral |
title_short | VACCINATIONS | Viral |
title_sort | vaccinations | viral |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150349/ http://dx.doi.org/10.1016/B0-12-370879-6/00418-X |
work_keys_str_mv | AT olszewskaw vaccinationsviral AT openshawpjm vaccinationsviral AT helsonr vaccinationsviral |